| Withdrawn | A Safety Study of Brentuximab Vedotin in Participants With HIV Human Immunodeficiency Virus | Phase 1 | 2022-12-31 |
| Terminated | A Study of SGN-ALPV in Advanced Solid Tumors Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | 2022-04-21 |
| Completed | A Study of SEA-CD40 Given With Other Drugs in Cancers Melanoma, Carcinoma, Non-Small- Cell Lung | Phase 2 | 2021-10-06 |
| Completed | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HE Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 / Phase 3 | 2021-03-22 |
| Terminated | A Study of SGN-STNV in Advanced Solid Tumors Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms | Phase 1 | 2021-01-18 |
| Terminated | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | Phase 1 | 2020-05-29 |
| Terminated | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing P Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | 2019-10-28 |
| Terminated | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous | Phase 2 | 2019-10-09 |
| Terminated | A Study of SGN-CD228A in Advanced Solid Tumors Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms | Phase 1 | 2019-09-03 |
| Terminated | A Safety Study of SGN-CD47M in Patients With Solid Tumors Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | 2019-07-17 |
| Completed | A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects Healthy | Phase 1 | 2019-05-08 |
| Completed | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (in Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | Phase 2 | 2019-03-20 |
| Completed | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin Drug-drug Interaction | Phase 1 | 2019-02-12 |
| Terminated | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Hodgkin Lymphoma | Phase 2 | 2019-01-28 |
| Completed | Effects of Tucatinib on Cardiac Repolarization in Healthy Participants Healthy | Phase 1 | 2018-12-06 |
| Terminated | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Multiple Myeloma | Phase 1 | 2018-11-01 |
| Completed | A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects Hepatic Impairment | Phase 1 | 2018-10-10 |
| Completed | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Drug-drug Interaction | Phase 1 | 2018-09-17 |
| Completed | A Trial of Tisotumab Vedotin in Cervical Cancer Cervical Cancer | Phase 2 | 2018-06-12 |
| Completed | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Ne Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | 2018-02-27 |
| Terminated | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma Multiple Myeloma | Phase 1 | 2018-02-20 |
| Completed | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Ovary Cancer, Cervix Cancer, Endometrium Cancer | Phase 2 | 2017-08-23 |
| Completed | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Metastatic Colorectal Adenocarcinoma | Phase 2 | 2017-06-23 |
| Terminated | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms | Phase 1 | 2017-02-23 |
| Terminated | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Multiple Myeloma | Phase 1 | 2016-12-01 |
| Terminated | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 | 2016-08-01 |
| Terminated | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymp Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL | Phase 2 | 2016-08-01 |
| Terminated | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Di Acute Myeloid Leukemia | Phase 3 | 2016-05-01 |
| Terminated | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma | Phase 1 | 2016-02-01 |
| Terminated | Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Un Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2016-02-01 |
| Completed | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2 HER2 Positive Breast Cancer | Phase 2 | 2016-01-28 |
| Completed | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Ovary Cancer, Cervix Cancer, Endometrium Cancer | Phase 1 / Phase 2 | 2015-11-30 |
| Terminated | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2015-11-01 |
| Completed | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Hodgkin Lymphoma | Phase 1 / Phase 2 | 2015-10-31 |
| Terminated | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lym Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b | Phase 2 | 2015-10-01 |
| Terminated | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2015-10-01 |
| Terminated | Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus Systemic Lupus Erythematosus | Phase 2 | 2015-07-01 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease | Phase 1 | 2015-02-28 |
| Completed | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML Acute Myeloid Leukemia, Acute Myelogenous Leukemia | Phase 1 | 2014-12-01 |
| Completed | Safety Study of SGN-CD70A in Cancer Patients Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma | Phase 1 | 2014-08-01 |
| Completed | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast C HER2 Positive Breast Cancers | Phase 1 | 2014-02-28 |
| Completed | A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic HER2 Positive Metastatic Breast Cancers | Phase 1 | 2013-12-31 |
| Completed | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Ovary Cancer, Cervix Cancer, Endometrium Cancer | Phase 1 / Phase 2 | 2013-11-30 |
| Completed | A Safety Study of SGN-LIV1A in Breast Cancer Patients HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 1 | 2013-10-22 |
| Terminated | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Larg Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse | Phase 2 | 2013-08-01 |
| Completed | A Safety Study of SGN-CD33A in AML Patients Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia | Phase 1 | 2013-07-01 |
| Completed | Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Hodgkin Disease | Phase 1 / Phase 2 | 2013-06-01 |
| Completed | A Safety Study of SGN-CD19A for B-Cell Lymphoma Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | Phase 1 | 2013-02-01 |
| Completed | A Safety Study of SGN-CD19A for Leukemia and Lymphoma Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | 2013-02-01 |
| Completed | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma | Phase 3 | 2013-01-31 |
| Completed | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL Hodgkin Disease, Peripheral T Cell Lymphoma | Phase 2 | 2012-10-31 |
| Terminated | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma Renal Cell Carcinoma | Phase 1 | 2012-08-01 |
| Completed | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts | Phase 2 | 2011-10-01 |
| Completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 2 | 2011-08-01 |
| Completed | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30- Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell | Phase 1 | 2011-02-01 |
| Completed | A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma Gastric Neoplasms, Pancreatic Neoplasms | Phase 1 | 2010-07-01 |
| Completed | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Followin Disease, Hodgkin | Phase 3 | 2010-04-30 |
| Completed | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | Phase 1 | 2010-01-01 |
| Completed | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma Disease, Hodgkin | Phase 1 | 2010-01-01 |
| Completed | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic | Phase 1 | 2009-12-01 |
| Completed | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin | Phase 1 | 2009-11-01 |
| Completed | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | Phase 2 | 2009-07-01 |
| Completed | A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | Phase 2 | 2009-03-01 |
| Completed | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Disease, Hodgkin | Phase 2 | 2009-02-01 |
| Completed | A Study of ARRY-380 in Patients With Advanced HER2+ Cancer Cancer | Phase 1 | 2008-05-01 |
| Completed | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 1 | 2008-04-01 |
| Terminated | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignan Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | Phase 1 | 2008-03-01 |
| Completed | A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) Myelodysplastic Syndrome (MDS) | Phase 1 | 2008-03-01 |
| Terminated | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients Wit Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 2 | 2007-09-01 |
| Completed | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML Acute Myeloid Leukemia | Phase 2 | 2007-09-01 |
| Completed | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma Multiple Myeloma | Phase 1 | 2007-08-01 |
| Completed | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | Phase 2 | 2006-12-01 |
| Completed | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Lymphoma, Non-Hodgkin, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic | Phase 1 | 2006-11-01 |
| Completed | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders | Phase 1 | 2005-11-01 |
| Completed | A Safety Study in Patients With Chronic Lymphocytic Leukemia Leukemia, Lymphocytic, Chronic | Phase 1 / Phase 2 | 2005-07-01 |
| Completed | A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma Non-Hodgkin Lymphoma | Phase 1 | 2004-12-01 |
| Completed | Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Large Cell Lymphoma | Phase 2 | 2004-09-01 |
| Completed | FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma Non-Small Cell Lung Carcinoma | Phase 2 | 2004-07-01 |
| Completed | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma Multiple Myeloma | Phase 1 | 2004-03-01 |
| Completed | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Anaplastic Large-Cell Lymphoma | Phase 2 | 2004-02-01 |
| Terminated | Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Breast Cancer | Phase 2 | 2000-10-01 |
| Completed | Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer Prostatic Neoplasms | Phase 2 | 2000-10-01 |
| Completed | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malign Hodgkin Disease, Lymphoma, Large-Cell, Sarcoma, Kaposi | Phase 1 / Phase 2 | — |
| Completed | Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma Carcinoma, Non-Small-Cell Lung | Phase 2 | — |
| No Longer Available | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 o Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | — | — |
| No Longer Available | Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer | — | — |
| Terminated | Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian C Ovarian Neoplasms | Phase 2 | — |
| Available | Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors | — | — |